From 2022 onwards, keywords such as “integrated analysis”, “positive NSCLC”, “lung adenocarcinoma”, and “lorlatinib” have emerged as new hotspots, indicating that future research will focus on ALK-positive NSCLC, particularly lung adenocarcinoma. Here, ALK is linked to non-small cell lung carcinoma.